Clinical Trial Update: A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis [Phase 3]

View source ↗

Summary

This document reports an ongoing Phase 3 clinical trial evaluating the efficacy and safety of BCD-281 for relapsing-remitting multiple sclerosis; recruitment is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• BCD-281

Snippet

Sponsor: Biocad | Conditions: Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | Status: RECRUITING